PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ASLAN Pharmaceuticals Limited (ASLN)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS04522R1014
CUSIP04522R101
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$11.58M
EPS-$2.75
Revenue (TTM)$12.00M
Gross Profit (TTM)$79.82M
EBITDA (TTM)-$43.71M
Year Range$0.39 - $4.69
Target Price$9.50
Short %0.52%
Short Ratio0.05

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


ASLAN Pharmaceuticals Limited

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in ASLAN Pharmaceuticals Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-60.00%-40.00%-20.00%0.00%20.00%40.00%NovemberDecember2024FebruaryMarchApril
-60.38%
22.58%
ASLN (ASLAN Pharmaceuticals Limited)
Benchmark (^GSPC)

S&P 500

Returns By Period

ASLAN Pharmaceuticals Limited had a return of -9.98% year-to-date (YTD) and -88.76% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-9.98%6.33%
1 month-28.06%-2.81%
6 months-59.17%21.13%
1 year-88.76%24.56%
5 years (annualized)-52.76%11.55%
10 years (annualized)N/A10.55%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
202430.72%28.94%-30.09%
2023-11.53%-40.43%-38.38%-24.36%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ASLN is 18, indicating that it is in the bottom 18% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of ASLN is 1818
ASLAN Pharmaceuticals Limited(ASLN)
The Sharpe Ratio Rank of ASLN is 2828Sharpe Ratio Rank
The Sortino Ratio Rank of ASLN is 2424Sortino Ratio Rank
The Omega Ratio Rank of ASLN is 2323Omega Ratio Rank
The Calmar Ratio Rank of ASLN is 44Calmar Ratio Rank
The Martin Ratio Rank of ASLN is 1414Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for ASLAN Pharmaceuticals Limited (ASLN) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ASLN
Sharpe ratio
The chart of Sharpe ratio for ASLN, currently valued at -0.42, compared to the broader market-2.00-1.000.001.002.003.00-0.42
Sortino ratio
The chart of Sortino ratio for ASLN, currently valued at -0.53, compared to the broader market-4.00-2.000.002.004.006.00-0.53
Omega ratio
The chart of Omega ratio for ASLN, currently valued at 0.93, compared to the broader market0.501.001.500.93
Calmar ratio
The chart of Calmar ratio for ASLN, currently valued at -0.90, compared to the broader market0.001.002.003.004.005.006.00-0.90
Martin ratio
The chart of Martin ratio for ASLN, currently valued at -1.30, compared to the broader market0.0010.0020.0030.00-1.30
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.91, compared to the broader market-2.00-1.000.001.002.003.001.91
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.77, compared to the broader market-4.00-2.000.002.004.006.002.77
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.46, compared to the broader market0.001.002.003.004.005.006.001.46
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.61, compared to the broader market0.0010.0020.0030.007.61

Sharpe Ratio

The current ASLAN Pharmaceuticals Limited Sharpe ratio is -0.42. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.42
1.91
ASLN (ASLAN Pharmaceuticals Limited)
Benchmark (^GSPC)

Dividends

Dividend History


ASLAN Pharmaceuticals Limited doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-99.08%
-3.48%
ASLN (ASLAN Pharmaceuticals Limited)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the ASLAN Pharmaceuticals Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ASLAN Pharmaceuticals Limited was 99.23%, occurring on Dec 26, 2023. The portfolio has not yet recovered.

The current ASLAN Pharmaceuticals Limited drawdown is 99.08%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.23%Jun 8, 20181397Dec 26, 2023
-10.31%May 31, 20181May 31, 20182Jun 4, 20183
-7.38%May 14, 201810May 25, 20181May 29, 201811
-2.32%May 7, 20181May 7, 20181May 8, 20182
-0.4%Jun 6, 20181Jun 6, 20181Jun 7, 20182

Volatility

Volatility Chart

The current ASLAN Pharmaceuticals Limited volatility is 22.89%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%50.00%100.00%150.00%NovemberDecember2024FebruaryMarchApril
22.89%
3.59%
ASLN (ASLAN Pharmaceuticals Limited)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of ASLAN Pharmaceuticals Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items